<?xml version="1.0" encoding="UTF-8"?>
<ref id="B120">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Kropeit</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>McCormick</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Erb-Zohar</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Moiseev</surname>
    <given-names>V. S.</given-names>
   </name>
   <name>
    <surname>Kobalava</surname>
    <given-names>Z. D.</given-names>
   </name>
   <name>
    <surname>Stobernack</surname>
    <given-names>H. P.</given-names>
   </name>
   <etal/>
  </person-group> (
  <year>2017</year>). 
  <article-title>Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment</article-title>. 
  <source>Br. J. Clin. Pharmacol.</source>
  <volume>83</volume> (
  <issue>12</issue>), 
  <fpage>2678</fpage>â€“
  <lpage>2686</lpage>. 
  <pub-id pub-id-type="doi">10.1111/bcp.13376</pub-id>
  <pub-id pub-id-type="pmid">28722153</pub-id>
 </mixed-citation>
</ref>
